Safety and Effectiveness Study of the Zenflow Spring System

Lower Urinary Tract Symptoms (LUTS) Clinical Trial

— BREEZE  

Official title:

Safety and Effectiveness Study of the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04987138
• Other study ID #: CLIN-0130
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 30, 2021
• Est. completion date: June 2026

Study information

• Verified date: April 2024
• Source: Zenflow, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.

Description:

Prospective, multi-center, multinational, 2:1 randomized, single-blinded, controlled clinical trial of the Zenflow Spring System. Patients randomized to the treatment group will undergo Zenflow Spring placement. Patients randomized to the control group will undergo a Sham procedure. Patients and site personnel administering follow-up assessments will be blinded to the randomized treatment through completion of the 3-month follow-up visit. Once a patient has completed their 3-month follow-up assessments, they will be unblinded. Following unblinding, patients who received a Sham procedure may elect to receive treatment with the Zenflow Spring System or alternatively they may exit the study. The duration of study participation is 60 months for patients who receive a Spring Implant and 3 months for subjects in the Control Arm.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 279
• Est. completion date: June 2026
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

1. Subject is able and willing to comply with all the assessments of the study,

2. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form,

3. = 45 years of age,

4. Baseline IPSS score = 13; = 1 in the IPSS voiding to storage sub-score ratio (IPSS-V/S),

5. Prostate volume 25 - 80 cc by transrectal ultrasound (TRUS), measured within 120 days post study consent,

6. Prostatic urethral length between 25 and 45 mm, as measured by cystoscopic pull-back,

7. Failed, intolerant, or subject choice to not take a medication regimen for the treatment of LUTS.

Exclusion Criteria:

1. Obstructive intravesical median prostatic lobe as determined by ultrasound (i.e., more than 10 mm intravesical prostatic protrusion on sagittal mid-prostate plane via abdominal ultrasound),

2. High bladder neck with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction as determined by the Investigator,

3. Urethral stricture, meatal stenosis, or bladder neck stricture - either current or recurrent,

4. Anatomical anomalies that will not accommodate the Implant, as determined by cystoscopy (e.g., prostatic urethral length to height geometry),

5. Requires indwelling catheter or intermittent catheterization to void,

6. Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng/mL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction),

7. One of the following baseline test results, taken from a single uroflowmetry reading:

1. Urinary volume void = 125mL (pre-bladder urinary volume of = 150 mL required),

2. Peak urinary flow rate (Qmax) of = 5 ml/second or > 15 mL/second,

3. Post- void residual volume (PVR) > 250 mL

8. History of other diseases causing voiding dysfunction including urinary retention (e.g., uncontrolled diabetes, diagnosis of neurogenic bladder, Parkinson's disease, multiple sclerosis, etc.),

9. Subjects with overactive bladder in the absence of benign prostatic obstruction,

10. Acute urinary tract infection (UTI) or finding of asymptomatic bacteriuria (Note:

subject can be enrolled if the UTI is treated and followed with a negative urine test result), or subjects with history of recurrent UTIs (defined as > 3 UTIs in the past 12 months),

11. Concomitant bladder stones,

12. Previous pelvic irradiation or radical pelvic surgery,

13. Previous prostate surgery, including: enucleation, resection, vaporization, thermotherapy, ablation, stenting or prostatic urethral lift,

14. Chronic prostatitis, recurrent prostatitis, chronic pelvic pain syndrome (CPPS), or painful bladder syndrome within the past 12 months

15. Known allergy to nickel,

16. Life expectancy less than 60 months,

17. Use of concomitant medications (e.g., anticholinergics, antispasmodics or tricyclic antidepressants) affecting bladder function,

18. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (Note: low dose aspirin therapy (81 mg) is permitted),

19. Taking 5-alpha-reductase inhibitors within 3 months of baseline evaluation,

20. Taking one of the following within 2 weeks of baseline evaluation:

1. alpha-blockers,

2. imipramine,

3. anticholinergics,

4. cholinergic gonadotropin releasing hormonal analogues,

5. Phosphodiesterase-5 Enzyme Inhibitors (Tadalafil) in doses for BPH,

6. Beta-3 adrenergic receptor agonist (Mirabegron),

21. Taking androgens, unless eugonadal state for at least 3 months or greater as documented by the Investigator,

22. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:

1. phenylephrine, or,

2. pseudoephedrine,

23. Future fertility concerns, or,

24. In the Investigator's opinion, the subject has a physical, psychological, or medical impairment that might prevent study completion or would confound study results (including subject questionnaires).

Related Conditions & MeSH terms

• BPH (Benign Prostatic Hyperplasia)
• Hyperplasia
• Lower Urinary Tract Symptoms
• Lower Urinary Tract Symptoms (LUTS)
• Prostatic Hyperplasia

Intervention

Device:
• Zenflow Spring System
The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
• Sham Procedure
A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.

Locations

Country	Name	City	State
United States	Midtown Urology Associates	Austin	Texas
United States	Urology Austin, PLLC	Austin	Texas
United States	Northshore University Health System	Glenview	Illinois
United States	Sheldon Freedman, MD, LTD	Las Vegas	Nevada
United States	American Institute of Research	Los Angeles	California
United States	Carolina Urologic Research Associates	Myrtle Beach	South Carolina
United States	Urology of Virginia, PLLC	Virginia Beach	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Zenflow, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety - The need for urinary catheterization	The rate of extended post-operative urinary catheterization (> 7 days from treatment) for inability to void among patients treated with the Zenflow Spring System.	Greater than 7 days after procedure
Primary	Safety - Adverse Events	The rate of device or procedure related serious adverse events in both the Treatment Arm and the Sham Arm.	Procedure through 12 months
Primary	Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH) as compared to Sham	The Treatment Arm will be considered superior to the Control Arm (Sham) when the mean 3-month improvement from baseline score for the IPSS symptom questionnaire demonstrates a minimum statistical margin of 25% compared to mean improvement from baseline for the Control Arm (Sham) alone.	Procedure to 3 months
Primary	Effectiveness- Symptoms Improvement	The mean percent change in IPSS in the treatment arm is at least 30% improvement over the Patient's pre-treatment baseline score.	Procedure to 12 months
Secondary	Safety - Adverse Events	Rate of device or procedure related adverse events at all time points.	Procedure through 60 months
Secondary	Safety - Pain Assessment Questionnaire	Comparison of pain at discharge to 2-week, 1- and, 3-month follow-up visits per Visual Analogue Scale (VAS) questionnaire. The VAS questionnaire asks the patient to indicate on a scale of 1 to 10 his level of pain where 1 is no pain and 10 is the worst pain.	Procedure through 3 months
Secondary	Safety - Sexual Health Questionnaire 1	Change in sexual health characterized by the questionnaire Sexual Health Inventory for Men (SHIM).	3 months post procedure through 24 months post procedure
Secondary	Safety - Sexual Health Questionnaire 2	Change in sexual health characterized by questionnaire Male Sexual Health Questionnaire - Ejaculatory Domain (MSHQ-EjD)	3 months post procedure through 24 months post procedure
Secondary	Safety - Device Removal	Assessment of adverse events outcomes related to a Spring Implant removal procedure.	Procedure through 60 months
Secondary	Safety - Classification of Adverse Events	Proportion of patients with adverse events classified as Clavien-Dindo Grade IIIb or higher or any event resulting in persistent disability	Procedure through 3 months
Secondary	Effectiveness - long term symptom improvement 1	Percent of patients who experience at least a 30 percent improvement in IPSS from their baseline pre-treatment score	Procedure through 12 months
Secondary	Effectiveness - long term symptom improvement 2	Mean percent change in IPSS in the treatment arm compared to baseline at all timepoints other than the primary endpoints.	Procedure through 60 months
Secondary	Effectiveness - flow metrics	Change from baseline in uroflowmetry measures of peak flow rate (Qmax)	1 month post procedure through 60 months
Secondary	Effectiveness - Re-intervention (device)	Post-procedure incidence of secondary reintervention using an alternate surgical LUTS therapy.	Procedure through 60 months
Secondary	Effectiveness - Re-intervention (drug)	Post-procedure incidence of secondary reintervention using standard pharmacological agents for LUTS therapy.	Procedure through 60 months